由于11％的临床研究地点未能招募一名患者，而37％的网站不足以注册，因此需要提高效率的需求。涉及较少站点的研究有可能改善这种表现，利用每个治疗领域的最佳领导者，降低旅行和行政成本，并使流程保持一致，以便于启动。
本洞察摘要研究了IQVIA对患者和现场参与的创新方法，例如开创性的早期计划，创新合作伙伴关系，新技术和通信工具，与患者倡导小组，精密注册和IQVIA Infosario Site网站网关平台合作。
介绍
Some 11% of research sites industry-wide fail to enroll a single patient, with 37% of sites under-enrolling, creating inefficiency and lost productivity.1 This represents a waste of time and money benefiting neither sponsors nor other research stakeholders. Studies involving fewer sites have potential to improve on this performance, taking advantage of the best leaders in each therapeutic area, reducing travel and administrative costs, and aligning processes for easier start-up.
涉及较少站点的研究具有提高临床试验效率，利用治疗专家的专业知识，最小化成本并优化流程以更轻松的启动方面的研究。
Early planning is a major factor in trial success – including identifying patient pathways in each country, understanding patient and investigator perspectives, and applying these insights to trial design and implementation. Patient advocacy groups are an important source of information about patient preferences, helping inform study design and tailored communication programs and flag potential enrollment and retention risks. For rare conditions, online sources of patient-generated content can also be mined using social listening tools to help understand how patients experience a particular condition. Early engagement with sites, clinical and medical teams, and in-country regulatory specialists is also critical to successful enrollment planning.
This insight brief examines new and innovative solutions to get drugs to patients faster, via improved patient and site engagement.